SCHEMBL1400994

SCHEMBL1400994

O=CNCCCCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
PRMT1 Q99873 1/20 0.54
NFKB1 P19838 2/20 0.52
TSHR P16473 2/20 0.52
PMP22 Q01453 1/20 0.52
ADRA1A P35348 1/20 0.50
MAPK1 P28482 1/20 0.48
ADH1B P00325 2/20 0.48
ADH1C P00326 2/20 0.48
ADH1A P07327 2/20 0.48
ADH7 P40394 2/20 0.48
SLC22A6 Q4U2R8 2/20 0.48
EPHX1 P07099 1/20 0.46
ADH4 P08319 1/20 0.46
GPR84 Q9NQS5 2/20 0.44
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
AKR1B1 P15121 1/20 0.44
CYP2D6 P10635 1/20 0.44
FOLH1 Q04609 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17760456 0.98 PRMT1 (0.58) LMNAPRMT1NFKB1TSHRPMP22
SCHEMBL7002091 0.98 PRMT1 (0.58) LMNAPRMT1NFKB1TSHRPMP22
SCHEMBL770728 0.98 PRMT1 (0.58) LMNAPRMT1NFKB1TSHRPMP22
SCHEMBL26904254 0.98 PRMT1 (0.58) LMNAPRMT1NFKB1TSHRPMP22
SCHEMBL1401106 0.95
Cyclohexane SCHEMBL5426084 0.89 EPHX2 (0.44) LMNAPRMT1NFKB1TSHRPMP22
SCHEMBL7340715 0.85 PRMT1 (0.50) LMNAPRMT1NFKB1TSHRPMP22
SCHEMBL842029 0.84
SCHEMBL17347892 0.83 EPHX2 (0.53) LMNAPRMT1TSHRADRA1AMAPK1
Hydrochloric Acid SCHEMBL10476094 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4170347-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2023-04-26 EP disclosed
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF Yamaguchi, Koushi (JP) 2023-04-06 US disclosed
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof Yamaguchi, Kouchi (JP) 2023-01-03 US disclosed
EP-3977995-A1 TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS Yamaguchi, Koushi (JP) 2022-04-06 EP disclosed
EP-3900729-A1 AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY Yamaguchi, Koushi (JP) 2021-10-27 EP disclosed
EP-3246036-B1 MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME YAMAGUCHI KOUSHI (JP) 2021-10-13 EP disclosed
CN-113226331-A Medicine for improving infertility or pregnancy state 山口晃史 2021-08-06 CN disclosed
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP YAMAGUCHI KOUSHI (JP) 2021-07-29 US disclosed
EP-3834826-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP Yamaguchi, Koushi (JP) 2021-06-16 EP disclosed
CN-112533599-A Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship 山口晃史 2021-03-19 CN disclosed
US-4983609-A Anticancer agents OTSUKA PHARMACEUTICAL (JP) 1991-01-08 US disclosed
US-4929611-A ANTIBODY INHIBITORS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-29 US disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
EP-0247381-A2 5-flurorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-02 EP disclosed
EP-0071926-B1 NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-10-08 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed
US-4479942-A Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-30 US disclosed
EP-0071926-A1 New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF PGF, SLC10A1, SLC26A4 LMNA 2424/4885PRMT1 1063/4885NFKB1 1572/4885
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof PGF, SLC10A1, SLC26A4 LMNA 2875/4885PRMT1 950/4885NFKB1 1846/4885
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP PGF, HAMP, HLA-DRB1 LMNA 4138/4885PRMT1 3244/4885NFKB1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.